Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 9/20 | 0.80 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.75 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.75 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19988246 | 0.92 | VDR (0.80) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL13859925 | 0.92 | VDR (0.80) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL14261171 | 0.91 | VDR (0.79) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL13644207 | 0.91 | VDR (0.79) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL13644205 | 0.91 | VDR (0.79) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL13644209 | 0.91 | VDR (0.79) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL9009932 | 0.90 | VDR (0.66) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL14357527 | 0.90 | VDR (0.66) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL14357530 | 0.90 | VDR (0.66) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL805084 | 0.89 | VDR (0.73) | VDRHDAC6HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018021-A1 | 2Alpha-Methyl and 2Beta-Methyl Analogs of 19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Their Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018021-A1 | 2Alpha-Methyl and 2Beta-Methyl Analogs of 19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Their Uses | CYP24A1, CYP27B1, CD14 | VDR 4/4885HDAC6 4390/4885HDAC3 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.